In the current study, we employed the EO771 syngeneic tumor model that has been previously shown to be responsive to both PS-targeting Abs (Bavituximab) [38] as well as anti-Mertk (a PS receptor belonging to the TAM family) [44]. This evidence concerns the gene MERTK and neoplasm.